Pulmonx (NASDAQ:LUNG) CEO Glendon French III Sells 67,813 Shares

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 67,813 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $96,972.59. Following the completion of the sale, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. This represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Pulmonx Price Performance

Shares of Pulmonx stock traded down $0.09 on Wednesday, reaching $1.44. The stock had a trading volume of 579,968 shares, compared to its average volume of 360,844. The business’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $1.79. Pulmonx Corporation has a fifty-two week low of $1.31 and a fifty-two week high of $8.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15.

Hedge Funds Weigh In On Pulmonx

Large investors have recently modified their holdings of the company. Cerity Partners LLC purchased a new position in shares of Pulmonx in the 4th quarter worth approximately $27,000. FNY Investment Advisers LLC purchased a new position in Pulmonx during the 3rd quarter valued at about $29,000. Opal Capital LLC purchased a new position in shares of Pulmonx during the 4th quarter valued at $29,000. Regatta Capital Group LLC bought a new position in Pulmonx in the 4th quarter worth about $30,000. Finally, Jain Global LLC purchased a new stake in Pulmonx in the third quarter valued at approximately $30,000. 91.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LUNG has been the topic of a number of research reports. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Finally, D. Boral Capital reiterated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Friday, February 20th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pulmonx presently has an average rating of “Hold” and a consensus target price of $6.81.

Key Headlines Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year credit facility of up to $60 million with Perceptive Advisors that includes a $40M term loan (with an option for an additional $20M tied to revenue milestones). Management says the financing extends debt maturity to 2031 and strengthens the balance sheet to support commercial and clinical priorities. Article Title
• Positive Sentiment: Q4 results showed improvement vs. a year ago: narrower GAAP loss ($0.25/sh) and adjusted EBITDA loss improved; full‑year 2025 revenue rose to $90.5M (up 8% YoY) and gross margin expanded to ~78% in Q4 — evidence of operating leverage and cost reductions. Article Title
• Neutral Sentiment: Management issued 2026 revenue guidance of $90M–$92M and expects ~75% gross margin with operating expenses $113M–$115M — guidance gives visibility but comes in below some analyst estimates, leaving mixed signals on near‑term topline momentum. Article Title
• Negative Sentiment: Several insiders sold stock on March 2 (including CEO Glendon E. French III, General Counsel David A. Lehman, CCO Geoffrey Beran Rose and Senior staff), representing multiple percent reductions in their holdings — heavy insider selling can pressure sentiment and amplify downside. SEC filings: CEO sale CEO Form 4, Lehman GC Form 4, Beran Rose CCO Form 4, Srikanth Radhakrishnan Form 4
• Negative Sentiment: Q4 U.S. revenue declined (~11% YoY) and total Q4 revenue was down ~5% YoY, signaling softer commercial momentum in Pulmonx’s largest market — the company emphasized a transition plan to reaccelerate U.S. sales, but near‑term growth risk weighed on the stock. Article Title

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.